Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Public ClinicalTrials.gov record NCT03259074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to demonstrate the impact of secukinumab on the progression of structural damage in the spine, as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) in patients with Ankylosing Spondylitis (AS).
Study identification
- NCT ID
- NCT03259074
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 859 participants
Conditions and interventions
Conditions
Interventions
- Placebo Biological
- GP2017 (adalimumab biosimilar) Biological
- AIN457 150 mg Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2017 (Actual)
- Primary completion
- Nov 12, 2021 (Actual)
- Completion
- Nov 29, 2021 (Actual)
- Last update posted
- Aug 21, 2023
2017 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Mesa | Arizona | 85202 | — |
| Novartis Investigative Site | Escondido | California | 92025 | — |
| Novartis Investigative Site | La Mesa | California | 91942 | — |
| Novartis Investigative Site | San Francisco | California | 94143 0138 | — |
| Novartis Investigative Site | Gainesville | Florida | 32607 | — |
| Novartis Investigative Site | Boise | Idaho | 83702 | — |
| Novartis Investigative Site | Shreveport | Louisiana | 71101 | — |
| Novartis Investigative Site | Wheaton | Maryland | 20902 | — |
| Novartis Investigative Site | Great Falls | Montana | 59405 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68516 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27408 | — |
| Novartis Investigative Site | Dayton | Ohio | 45402 | — |
| Novartis Investigative Site | Middleburg Heights | Ohio | 44130 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| Novartis Investigative Site | Duncansville | Pennsylvania | 16635 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38119 | — |
| Novartis Investigative Site | Mesquite | Texas | 75150 | — |
| Novartis Investigative Site | Kennewick | Washington | 99336 | — |
| Novartis Investigative Site | Franklin | Wisconsin | 53132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 152 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03259074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2023 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03259074 live on ClinicalTrials.gov.